Gainers

• Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report came out yesterday.
• Akanda (NASDAQ:AKAN) shares rose 57.27% to $7.88. The market value of their outstanding shares is at $2.7 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 32.5% to $4.37. The market value of their outstanding shares is at $1.7 million.
• Valneva (NASDAQ:VALN) stock rose 28.14% to $7.24. The market value of their outstanding shares is at $576.9 million. The company's, Q2 earnings came out yesterday.
• HeartFlow (NASDAQ:HTFL) stock increased by 25.77% to $39.0. The market value of their outstanding shares is at $2.6 billion. As per the news, the Q2 earnings report came out yesterday.
• Eton Pharmaceuticals (NASDAQ:ETON) shares moved upwards by 22.79% to $50.1. The company's market cap stands at $1.1 billion. As per the press release, Q2 earnings came out yesterday.

Losers

• BeyondSpring (NASDAQ:BYSI) stock fell 19.6% to $0.8 during Friday's pre-market session. The company's market cap stands at $40.9 million.
• Healthcare Triangle (NASDAQ:HCTI) stock declined by 18.5% to $1.41. The company's market cap stands at $3.5 million. As per the press release, Q2 earnings came out yesterday.
• Zentalis Pharmaceuticals (NASDAQ:ZNTL) stock fell 15.67% to $3.5. The company's market cap stands at $297.4 million.
• Innate Pharma (NASDAQ:IPHA) stock declined by 15.19% to $2.15. The market value of their outstanding shares is at $237.8 million.
• NewcelX (NASDAQ:NCEL) stock fell 14.45% to $3.08. The company's market cap stands at $19.3 million.
• Cibus (NASDAQ:CBUS) stock declined by 13.69% to $1.64. The company's market cap stands at $145.0 million. The company's, Q2 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.